Selecta Biosciences (SELB) News Today → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free SELB Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 6, 2024 | msn.comCraig David says Leigh Francis' Bo Selecta! skit 'sent him down a dark road'January 23, 2024 | yahoo.comSelb, Germany - Weather Forecasts | Maps | News - Yahoo WeatherDecember 15, 2023 | investing.comCartesian Therapeutics Inc (RNAC)November 14, 2023 | finance.yahoo.comFurther weakness as Selecta Biosciences (NASDAQ:SELB) drops 17% this week, taking five-year losses to 85%November 13, 2023 | bizjournals.comPared-down Selecta merges with Maryland biotechNovember 13, 2023 | msn.comSelecta Biosciences Merges With Cartesian To Focus On Autoimmune Cell TherapyNovember 13, 2023 | markets.businessinsider.comSelecta Biosciences Merges With Cartesian Therapeutics In All-stock DealNovember 13, 2023 | marketbeat.comTrading was temporarily halted for "SELB" at 08:11 AM with a stated reason of "News pending."November 11, 2023 | benzinga.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Selecta Biosciences, Inc. (NASDAQ: SELB) and Encourages Investors to Contact the FirmNovember 10, 2023 | morningstar.comSelecta Biosciences Inc SELBOctober 31, 2023 | marketwatch.comSelecta Biosciences in Deal to Transfer Manufacturing, Development Rights of Sel-212 TreatmentOctober 31, 2023 | finance.yahoo.comSelecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner SobiOctober 25, 2023 | msn.comSelecta Biosciences files for $200M mixed shelfAugust 19, 2023 | msn.comMizuho Maintains Selecta Biosciences (SELB) Buy RecommendationAugust 19, 2023 | msn.comSVB Leerink Downgrades Selecta Biosciences (SELB)August 18, 2023 | markets.businessinsider.comAnalyst Ratings for Selecta BiosciencesAugust 18, 2023 | msn.comNeedham Maintains Selecta Biosciences (SELB) Buy RecommendationAugust 18, 2023 | markets.businessinsider.comSelecta Biosciences (SELB) Gets a Buy from H.C. WainwrightAugust 18, 2023 | marketbeat.comSelecta Biosciences (NASDAQ:SELB) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPSSelecta Biosciences (NASDAQ:SELB - Get Free Report) announced its earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.05. Selecta Biosciences had a negative net margin of 18.21% and a negative return on equity of 17.67%. The company had revenue of $5.25 million for the quarter, compared to analysts' expectations of $9.90 million.August 18, 2023 | marketbeat.comSelecta Biosciences' (SELB) "Market Perform" Rating Reaffirmed at SVB LeerinkSVB Leerink reaffirmed a "market perform" rating and issued a $1.00 price target on shares of Selecta Biosciences in a report on Friday.August 17, 2023 | markets.businessinsider.comMizuho Securities Reaffirms Their Buy Rating on Selecta Biosciences (SELB)August 17, 2023 | finance.yahoo.comQ2 2023 Selecta Biosciences Inc Earnings CallAugust 17, 2023 | msn.comSelecta Biosciences Narrows R&D Focus On Gout CandidateAugust 17, 2023 | finance.yahoo.comSelecta Biosciences, Inc. (SELB) Reports Q2 Loss, Misses Revenue EstimatesAugust 17, 2023 | finance.yahoo.comSelecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 EconomicsJuly 14, 2023 | finance.yahoo.comSelecta Biosciences, Inc.'s (NASDAQ:SELB) largest shareholders are individual investors with 35% ownership, institutions own 26%June 9, 2023 | marketbeat.comSelecta Biosciences (NASDAQ:SELB) Rating Lowered to Hold at StockNews.comStockNews.com cut Selecta Biosciences from a "buy" rating to a "hold" rating in a report on Friday.June 8, 2023 | marketbeat.comSelecta Biosciences, Inc. (NASDAQ:SELB) Shares Sold by GSA Capital Partners LLPGSA Capital Partners LLP cut its holdings in shares of Selecta Biosciences, Inc. (NASDAQ:SELB - Get Rating) by 48.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 372,087 shares of theJune 6, 2023 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 119,611 Shares of Selecta Biosciences, Inc. (NASDAQ:SELB)Connor Clark & Lunn Investment Management Ltd. decreased its holdings in shares of Selecta Biosciences, Inc. (NASDAQ:SELB - Get Rating) by 81.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,239 shJune 3, 2023 | finance.yahoo.comSelecta Biosciences (NASDAQ:SELB) shareholders are up 22% this past week, but still in the red over the last five yearsMay 31, 2023 | finance.yahoo.comSelecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of RheumatologyMay 12, 2023 | marketbeat.comSelecta Biosciences, Inc. (NASDAQ:SELB) Receives Consensus Rating of "Moderate Buy" from BrokeragesSelecta Biosciences, Inc. (NASDAQ:SELB - Get Rating) has been given a consensus recommendation of "Moderate Buy" by the seven brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendatMay 9, 2023 | finance.yahoo.comNewsflash: Selecta Biosciences, Inc. (NASDAQ:SELB) Analysts Have Been Trimming Their Revenue ForecastsMay 8, 2023 | msn.comHC Wainwright & Co. Reiterates Selecta Biosciences (SELB) Buy RecommendationMay 5, 2023 | marketbeat.comStockNews.com Downgrades Selecta Biosciences (NASDAQ:SELB) to HoldStockNews.com cut Selecta Biosciences from a "buy" rating to a "hold" rating in a research note on Friday.May 5, 2023 | bizjournals.comSelecta cuts in-house gene therapy programs, lays off 15May 4, 2023 | markets.businessinsider.comMizuho Securities Sticks to Their Buy Rating for Selecta Biosciences (SELB)May 4, 2023 | finance.yahoo.comSelecta Biosciences, Inc. (SELB) Reports Q1 Loss, Misses Revenue EstimatesMay 4, 2023 | finanznachrichten.deSelecta Biosciences, Inc.: Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 4, 2023 | finance.yahoo.comSelecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business UpdateApril 28, 2023 | finance.yahoo.comSelecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business UpdateApril 18, 2023 | finance.yahoo.comInvestors Holding Back On Selecta Biosciences, Inc. (NASDAQ:SELB)April 13, 2023 | msn.comNeedham Reiterates Selecta Biosciences (SELB) Buy RecommendationApril 13, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Selecta BiosciencesApril 13, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Selecta Biosciences (SELB) and Denali Therapeutics (DNLI)March 27, 2023 | finance.yahoo.comIs Selecta Biosciences, Inc.'s (NASDAQ:SELB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?March 22, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Selecta BiosciencesMarch 22, 2023 | marketbeat.comMizuho Cuts Selecta Biosciences (NASDAQ:SELB) Price Target to $4.00Mizuho reduced their price target on shares of Selecta Biosciences from $5.00 to $4.00 in a research note on Wednesday.March 22, 2023 | markets.businessinsider.comBTIG Sticks to Their Buy Rating for Selecta Biosciences (SELB)March 21, 2023 | finance.yahoo.comSelecta, SOBI's Chronic Refractory Gout Program Meets Primary Goal, US Submission Expected Next Year Get Selecta Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SELB and its competitors with MarketBeat's FREE daily newsletter. Email Address What’s Really Next for America… (Ad)Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly. Click here to stream this controversial exposé now. SELB Media Mentions By Week SELB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SELB News Sentiment▼0.000.57▲Average Medical News Sentiment SELB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SELB Articles This Week▼00▲SELB Articles Average Week Get Selecta Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SELB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LianBio News Today FibroGen News Today Syros Pharmaceuticals News Today Sagimet Biosciences News Today Cardiol Therapeutics News Today PDS Biotechnology News Today DiaMedica Therapeutics News Today Repare Therapeutics News Today Amylyx Pharmaceuticals News Today FitLife Brands News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SELB) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport SocietyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Selecta Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
